INS and metabolic dysfunction-associated steatotic liver disease: Consequences of NAFLD/NASH include reduced whole-body hepatic and adipose tissue insulin sensitivity (Bugianesi et al., 2010) as well as an increased risk of cardiovascular events (Targher et al., 2020), T2D, and all-cause mortality (Targher et al., 2020).